Generic Company Disclosure Could Be A 'Speedbump' Against Misuse Of US FDA Access Inquiry List
Executive Summary
Generic companies might get more transparency than they bargained for if there is misuse of the public list of reference drugs they say they have trouble obtaining; at BIO annual meeting, FDA Commissioner Gottlieb also suggests VA procurement of brand drugs as possible alternative if innovators continue to hinder access for bioequivalence testing.
You may also be interested in...
Biosimilars For US Market May Be Able To Rely On EU-Licensed Reference Products
Commissioner Scott Gottlieb says move could allow biosimilar sponsors to avoid anti-competitive efforts by brand sponsors in US.
Biosimilars For US Market May Be Able To Rely On EU-Licensed Reference Products
Commissioner Scott Gottlieb says move could allow biosimilar sponsors to avoid anti-competitive efforts by brand sponsors in US.
REMS Abuse Website: Celgene, Actelion Top List Of Suspected 'Gamers'
Other sponsors could be using tactics other than REMS abuse to game the system, US FDA Commissioner Scott Gottlieb says.